SARS-CoV
SARS coronavirus
SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).
CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.
All Product Categories
-
SARS-CoV Related Products (1195)
Related Products (1195)
-
Recombinant Proteins (196)
-
Artecanin
0 ImagesCat. No.: HY-127083CAS No.: 29431-84-3Artecanin is a SARS-CoV-2 main protease (Mpro) inhibitor with predicted high gastrointestinal absorption and oral bioavailability, and no predicted hepatotoxicity, carcinogenicity, mutagenicity or cytotoxicity. Artecanin interacts with His41 and Cys145, the key amino acid residues in the active site of Mpro, blocks the cleavage and maturation of viral precursor proteins, and forms a stable complex with Mpro. Artecanin blocks the invasion of SARS-CoV-2. Artecanin is applicable to the research of COVID-19.
-
SARS-CoV-2 Mpro-IN-43
0 ImagesCat. No.: HY-172965SARS-CoV-2 Mpro-IN-43 (Compound 1) is a coronavirus main protease (Mpro) inhibitor (IC50: 72 μM). SARS-CoV-2 Mpro-IN-43 interacts with key residues in the active site of Mpro via non-covalent binding, exerting its anti-coronavirus effect. SARS-CoV-2 Mpro-IN-43 exhibits moderate to low cytotoxicity, with CC50 values of 13.24, 41.02, and 42.26 µM in HaCaT, HEK293T, and HepG2 cells, respectively. SARS-CoV-2 Mpro-IN-43 can be used in anti-SARS-CoV-2 research.
-
NSC111552
0 ImagesCat. No.: HY-153719CAS No.: 40420-48-2NSC111552 is a potent SARS-CoV-2 NSP14 MTase inhibitor. NSC111552 inhibits the FL-NAH binding to the SARS-CoV-2 NSP14 MTase with an IC50 of 5.1 μM.
-
Antimicrobial agent-11
0 ImagesCat. No.: HY-151501Antimicrobial agent-11 is a SARS-CoV-2 inhibitor with antibacterial activity.
-
SARS 3CLpro-IN-1
0 ImagesCat. No.: HY-150691CAS No.: 2409178-86-3SARS 3CLpro-IN-1 (Compound 3b) is a SARS 3CL protease inhibitor with an IC50 value of 95 μM, as a specific stereo isomer of the octahydroisochromene scaffold, directs the P1 site imidazole.
-
SARS-CoV-2-IN-84
0 ImagesCat. No.: HY-162414CAS No.: 214221-82-6SARS-CoV-2-IN-84 (compound 20) is aSARS-CoV-2 inhibitor that targets the 3CL protease (3CL Pro) of SARS-CoV-2 (IC50: 369.5 nM ).
-
Antioxidant agent-9
0 ImagesCat. No.: HY-P4307CAS No.: 71835-79-5Antioxidant agent-9 is a peptide with the sequence Asp-Trp. Antioxidant agent-9 shows antioxidant activity. Antioxidant agent-9 also is potential as SARS-CoV-2 antiviral, with an affinity strength equal to Chloroquine (HY-17589A) and Favipiravir (HY-14768).
-
SARS-CoV-2-IN-11
0 ImagesCat. No.: HY-145277CAS No.: 2722635-28-9SARS-CoV-2-IN-11 is a potent and nontoxic inhibitor of SARS-CoV-2 3CL protease (3CLpro) with an IC50 and EC50 of 0.17 and 1.45 nM, respectively. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
-
Pamaqueside
0 ImagesCat. No.: HY-105086CAS No.: 150332-35-7Synonyms: CP148623Pamaqueside (CP148623) is a cholesterol absorption inhibitor and a potent binder of the SARS-CoV-2 receptor-binding domain (RBD), which may inhibit viral cellular entry. Pamaqueside can be utilized in metabolic and antiviral research.
-
M56-S2 iodide
0 ImagesCat. No.: HY-155416CAS No.: 1101867-17-7M56-S2 iodide is a SARS-CoV-2 Mpro inhibitor (IC50=4.0 μM). M56-S2 iodide showed good oral bioavailability and low toxicity in ADMET prediction. M56-S2 iodide has good drug potential and can be used in antiviral (such as SARS-CoV-2) research.
-
ZINC61142882
0 ImagesCat. No.: HY-149319CAS No.: 3034181-87-5ZINC61142882 is an inhibitor of the SARS-CoV-2 Nsp14 N7-Methyltransferase (IC50: 6 μM).
-
FWM-4
0 ImagesCat. No.: HY-144799CAS No.: 2757194-03-7FWM-4 is a potent SARS-COV-2 NSP13 helicase enzyme inhibitor.
-
ZINC4497834
0 ImagesCat. No.: HY-169256CAS No.: 767310-01-0ZINC4497834 is an inhibitor of SARS-CoV-2 major protease Mpro. ZINC4497834 can be used in anti-COVID19 research.
-
SARS-CoV-2 3CLpro-IN-5
0 ImagesCat. No.: HY-151535CAS No.: 2913186-57-7SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor of 3C-like protease (3CLpro). SARS-CoV-2 3CLpro-IN-5 has inhibitory activity for 3CLpro with an IC50 value of 3.8 nM. SARS-CoV-2 3CLpro-IN-5 has 9.0% oral bioavailability (BA). SARS-CoV-2 3CLpro-IN-5 can be used for the research of coronavirus disease 2019 (COVID-19).
